Core Insights - The 2025 Guizhou Top 100 Private Enterprises and Top 20 Private Manufacturing Enterprises were announced, showcasing the resilience and vitality of the private economy in Guizhou, which is becoming a significant force for high-quality development in the province [2][11]. Group 1: Rankings and Performance - The threshold for entering the 2025 Guizhou Top 100 Private Enterprises is set at 693 million yuan, an increase of 51 million yuan or 7.94% from the previous year [11]. - The total revenue of the top 100 enterprises reached 294.69 billion yuan, an increase of 7.96 billion yuan or 2.78% year-on-year [11]. - The manufacturing sector remains dominant, comprising over 60% of the top 100 enterprises, with 62 companies in this category [11]. Group 2: Characteristics of Top Enterprises - The top 100 enterprises exhibit five key characteristics: leading enterprises continue to excel, with three companies reporting revenues exceeding 10 billion yuan; the industrial structure is continuously optimized; R&D investment has significantly increased, with 2024 R&D expenses reaching 5.396 billion yuan, a year-on-year increase of 25.49% [11]. - There is a growing awareness of legal compliance and integrity, with 82 enterprises establishing legal risk control systems and 62 implementing bidding management systems [11]. - Social responsibility is actively pursued, with 51 enterprises participating in rural revitalization efforts, contributing to employment stability with an average of 1,738 jobs created per enterprise [11]. Group 3: Notable Companies - Zhongwei New Materials Co., Ltd. ranks first in the 2025 Guizhou Top 100 Private Enterprises, followed by Guizhou Tongyuan Group and Guizhou Geely Automobile Manufacturing Co., Ltd. [12][23]. - In the Top 20 Private Manufacturing Enterprises, Zhongwei New Materials Co., Ltd. also leads, followed by Guizhou Geely Automobile Manufacturing Co., Ltd. and Guiyang Hisense Electronics Co., Ltd. [23].

Core Viewpoint - Sanli Pharmaceutical has signed a technology transfer contract with Hainan University for the HXW2324 compound and related patent application rights, aiming to enhance its innovative drug product portfolio through collaboration with academic research [1] Group 1: Contract Details - The total transfer price for the HXW2324 compound is 200 million RMB, which includes a milestone payment of 20 million RMB and a sales commission of 180 million RMB [1] - The contract is designed to integrate the company's industrialization capabilities with university research resources to promote the transformation of innovative drug research results [1] Group 2: Product Information - The HXW2324 compound is a preclinical candidate for developing new treatments for Alzheimer's disease (AD) [1]

Group 1 - Xusheng Group's actual controller has changed to the Guangzhou Municipal Government, with stock resuming trading on December 23, 2025 [1] - Lingyun Light plans to invest up to $5 million in the IPO of Zhipu Hong Kong as a cornerstone investor [1] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuan Robotics to enhance collaboration in the development of dexterous hands [2] Group 2 - Hualian Holdings intends to acquire 100% of the Canadian company Argentum Lithium S.A. for $175 million, which is approximately 1.235 billion yuan [3] - Shiyuan Zhaoye plans to raise no more than 550 million yuan through a convertible bond issuance for the Zhuhai Shiyuan Jingguan Garden project [4] - ST Quanwei and its subsidiary are involved in a civil mediation agreement involving 69.0158 million yuan [4] Group 3 - Jiao Jian Co.'s actual controller has been subjected to criminal coercive measures, but the company's control has not changed [5] - Tianji Technology is facing a lawsuit for alleged collusion in bidding, but its operations remain normal [5] - Jinpan Technology plans to issue 1.672 billion yuan in convertible bonds for data center power modules and other projects [5] Group 4 - Hongqi Chain's shareholder Yonghui Supermarket plans to reduce its stake by up to 3% [6] - Shuangqiang Technology's director did not implement a planned share reduction [7] - Zhuoran Co.'s subsidiary has signed a significant order worth 4.033 billion yuan [8] Group 5 - ST Zhitong's stock will have its risk warning lifted on December 24, 2025, with a change in trading limits [9] - Yingwei Co. plans to reduce its stake by up to 0.56% [10] - Huaxia Happiness's board rejected five temporary proposals from China Ping An Life Insurance [11] Group 6 - China Nonferrous Metals plans to acquire 99.9% of Raura Company for $106 million [11] - Sanhua Intelligent Control expects a net profit of 3.874 billion to 4.649 billion yuan for 2025, a year-on-year increase of 25% to 50% [11] - Chaoxun Communication received a government subsidy of 18.0455 million yuan [12] Group 7 - Jiangfeng Electronics plans to transfer 4% of Shanghai Runping's equity for 60 million yuan [12] - Dingyang Technology has launched a 20 GHz high-bandwidth digital oscilloscope [13] - Linyi Intelligent plans to acquire 35% of Dongguan Liminda Electronics for 875 million yuan [14] Group 8 - Trina Solar has sold its U.S. 5GW module factory to T1, receiving $100 million in cash and shares [14] - Aihua Packaging's major shareholder reduced its stake by 700,000 shares during the stock's abnormal fluctuation period [14] - China Merchants Bank has approved a comprehensive credit limit of 165 billion yuan for China Merchants Group [15] Group 9 - Lingwei Technology plans to acquire 70% of Jiangsu Huimai for 50.2 million yuan [16] - Yongding Co. is increasing its capital by 600 million yuan for its polysilicon subsidiary [19] - Zhong'an Technology's subsidiary is voluntarily extending its share lock-up period by six months [19] Group 10 - Xiangyu Medical's brain-computer interface products have entered over 500 top-tier hospitals, with a target of 700 by the Spring Festival [18] - Wenda Technology's major shareholder has terminated its share reduction plan [18] - Wenta Technology's major shareholder reduced its stake by 1.2097 million shares [18]

（文章来源：证券日报） 证券日报网讯 12月22日晚间，三力制药发布公告称，公司第四届董事会第十九次会议审议通过《关于 公司与海南大学签署技术转让合同的议案》。 ...

Core Viewpoint - Sanli Pharmaceutical has signed a technology transfer contract with Hainan University for the acquisition of the compound HXW2324 and related patent application rights, aiming to enhance its innovative drug product portfolio and align with its long-term strategic goals [1] Group 1: Technology Transfer Agreement - The total transfer price for the invention patent rights or patent application rights is set at 200 million yuan, which includes a milestone payment of 20 million yuan (tax included) and a sales commission of 180 million yuan (tax included) [1] - The compound HXW2324 is a preclinical candidate for developing new treatments for Alzheimer's disease [1] Group 2: Company Background and Financials - Sanli Pharmaceutical's main business includes the research, production, and sales of pharmaceuticals, with key products such as throat spray for children, Qi Jiao Sheng Bai capsules, and others [1] - In the first three quarters of this year, the company achieved operating revenue of 1.038 billion yuan and a net profit attributable to shareholders of 81 million yuan [1]

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

Core Viewpoint - The company has signed a technology transfer contract with Hainan University to acquire the patent application rights for the HXW2324 compound, aimed at developing a new treatment for Alzheimer's disease, enhancing its innovative drug product portfolio and market competitiveness [1][2]. Group 1: Technology Transfer Agreement - The total transfer price for the patent rights is set at 200 million RMB, which includes a milestone payment of 20 million RMB and a sales commission of 180 million RMB [2]. - The initial milestone payment of 3 million RMB is contingent upon Hainan University conducting efficacy studies on the HXW2324 compound using three classic Alzheimer's disease animal models, with results needing mutual agreement for further research [2][3]. Group 2: Project Terms and Conditions - The project can be terminated by either party if deemed unnecessary, and sales commissions will be paid at a rate of 2 RMB per box (including VAT) until the total sales commission reaches 180 million RMB or five years have passed since the first commission withdrawal [3]. - The company has indicated that the contract's execution will not significantly impact its financial status or operating performance for the current year, although drug development is inherently risky and subject to various unpredictable factors [3]. Group 3: Company Strategy and Brand Image - The company has changed its stock abbreviation from "Guizhou Sanli" to "Sanli Pharmaceutical" to better reflect its main business and strengthen its brand image [4]. - The company has established a biopharmaceutical fund with a total scale of 500 million RMB, focusing on equity investment projects in biotechnology and health management, aiming to build a comprehensive investment ecosystem in the innovative drug sector [4].

Core Viewpoint - Guizhou Sanli Pharmaceutical Co., Ltd. has successfully passed a board resolution to sign a technology transfer contract with Hainan University, marking a significant step in the company's strategic layout in technological innovation [1] Group 1: Board Meeting Details - The fourth board meeting was held on December 22, 2025, with all nine directors present, and the resolution was passed unanimously [1] - The technology transfer contract was previously reviewed and approved by the company's Strategic Committee [1] Group 2: Implications of the Technology Transfer - The technology transfer is expected to have a potential impact on the company's product line expansion and enhancement of core competitiveness [1] - The specific details of the technology transfer contract will be disclosed in a separate announcement [1]

证券代码：603439 证券简称：三力制药 公告编号：2025-074 贵州三力制药股份有限公司 关于与海南大学签署技术转让合同的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 贵州三力制药股份有限公司（以下简称"公司"）于近日与海南大学签署了 《技术转让（专利申请权）合同》（以下简称"技术转让合同"）。本次校企合 作，旨在通过加强交流与合作，实现校企间资源共享、优势互补，通过整合公司 产业化能力与高校研发资源，推动创新药物科研成果转化，助力公司拓展创新药 产品布局，提升公司市场竞争优势。 根据《公司章程》及公司相关制度的规定，本次合同的签署不需要提交公司 股东会审议。本次合同的签订不构成关联交易，亦不构成《上市公司重大资产重 组管理办法》规定的重大资产重组，无需经有关部门批准。 二、交易对方的基本情况 单位名称：海南大学 1 本次公司签署的《技术转让（专利申请权）合同》系确立双方合作意向，具 体项目实施进度和最终成果尚存在不确定性，敬请广大投资者理性投资，注 意投资风险。 已履行的审议程序：公司于 2025 年 12 ...

贵州三力制药股份有限公司 第四届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 2025 年 12 月 22 日，贵州三力制药股份有限公司（"公司"）第四届董事会 第十九次会议在公司会议室以现场和通讯表决方式召开。本次会议的会议通知和 材料于 2025 年 12 月 16 日以书面及通讯等方式送达所有参会人员。本次会议应 到董事 9 人，实到董事 9 人。本次会议由董事长张海先生召集和主持，本次会议 无列席人员。会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的有关规定，会议决议合法有效。 二、董事会会议审议情况 证券代码：603439 证券简称：三力制药 公告编号：2025-073 表决情况：9 票同意，0 票回避，0 票反对，0 票弃权，表决结果：通过。 具体内容详见同日于上海证券交易所网站（www.sse.com.cn）及指定媒体披 露的《贵州三力制药股份有限公司关于与海南大学签署技术转让合同的公告》（公 告编号：2025-074）。 1 特此公告 ...